CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Diagnosis of Vaginitis — Coverage Criteria

Defines coverage and limitations for diagnostic testing of vaginitis (BV, VVC, trichomoniasis and mixed vaginitis) for symptomatic individuals and screening in specified populations; applies to Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyDiagnosis of Vaginitis — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionFor symptomatic individuals, document symptoms and perform initial tests (pH, amine test, wet mount/KOH) and use NAAT/PCR or other covered molecular tests only with supporting clinical signs or risk factors.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2assays with FDA clearance mentioned

9covered tests

3not-covered items

4.0-4.5normal premenopausal pH

>=95%Aptima BV sensitivity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered testing

Covered when clinically indicated for symptomatic individuals or specific risk factors:

Initial/office testing for symptomatic vaginitis: Measurement of vaginal pH; amine (whiff) test; saline wet mount; KOH (hydrogen peroxide) wet mount; microscopic examination of vaginal fluids

Meets coverage criteria for symptomatic individuals

Molecular and culture tests meeting coverage: Direct probe DNA-based identification of Gardnerella, Trichomonas, and Candida (e.g., BD Affirm VPIII); NAAT/PCR for Trichomonas vaginalis; measurement of sialidase activity for BV; vaginal cultures for Candida when wet-mount negative and pH normal; PCR-based identification of Candida for complicated VVC

Each of these meets coverage when used for symptomatic individuals or appropriate clinical scenarios

Screening for Trichomonas in persons with risk factors: Screening for Trichomonas meets coverage for individuals with risk factors (new/multiple partners, history of STIs especially HIV, exchange of sex for payment, incarceration, injection drug use)

Meets coverage criteria

Not Medically Necessary / Not Covered

Not covered:

NAAT panels for multiple vaginitis types: NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis; e.g., BD MAX Vaginal Panel, NuSwab VG, Xpert Xpress MVP) does not meet coverage criteria

Listed explicitly as not meeting coverage

Screening in asymptomatic individuals: Screening for trichomoniasis and bacterial vaginosis in asymptomatic individuals, including asymptomatic pregnant persons at average or high risk for preterm labor, does not meet coverage criteria

Listed explicitly as not meeting coverage

Other non-supported tests: Rapid identification of Trichomonas by enzyme immunoassay; molecular-based panel testing for vaginal flora imbalance and/or infertility; and other tests for vaginitis not addressed above do not meet coverage criteria

Listed explicitly as not meeting coverage

Molecular NAAT/PCR testing for symptomatic vaginitis

Covered when ALL of the following are met

Symptomatic testing indication: Patient is symptomatic (vaginal discharge, odor, itch, or other vaginal symptoms) and clinical evaluation suggests vaginitis

CDC states BV NAATs should be used among symptomatic women only; accuracy not well defined for asymptomatic women

Appropriate test selection: Use of NAAT/PCR assays (including FDA-cleared Aptima BV and BD MAX Vaginal Panel or internally validated LDTs) for detection of BV, Candida species, and Trichomonas vaginalis is limited to symptomatic patients or when microscopy/Amsel/Nugent are unavailable

Two assays are FDA-cleared; other assays are laboratory-developed tests requiring internal validation

Specimen collection: Clinician- or patient-collected vaginal swabs are acceptable per assay IF the assay supports that collection method

Studies reported similar performance for clinician- and patient-collected samples for Aptima assays

Diagnostic testing coverage criteria

Covered when testing is used to diagnose symptomatic vaginitis or to confirm diagnosis in clinically indicated situations

Primary coverage conditions: Testing with molecular assays (including FDA-cleared BD MAX Vaginal Panel and Aptima BV) is intended to aid in diagnosis of BV, Candida species, and Trichomonas vaginalis in females with clinical presentation consistent with vaginitis/vaginosis; clinician- or patient-collected vaginal swabs are acceptable per test labeling.

Supported by FDA indications and guideline statements

Preferred diagnostic approaches per professional societies: For BV diagnosis, use Amsel criteria or Gram stain with Nugent scoring; for trichomoniasis, NAAT/NAAT-like testing is recommended; for VVC, require visualization on wet-mount or positive culture/commercial diagnostic test in symptomatic patients.

ACOG and IDSA recommendations cited

Use of LDTs and laboratory responsibilities: Laboratory-developed tests (LDTs) may be used but must be internally validated and are regulated under CLIA as high-complexity tests; they are not FDA-cleared but may be used for clinical care when validated.

Asymptomatic screening for trichomoniasis and bacterial vaginosis is not supported by this policy. Specifically, screening for these conditions in asymptomatic individuals — including asymptomatic pregnant persons at average or high risk for preterm labor — DOES NOT MEET COVERAGE CRITERIA and may be denied because available evidence does not establish clinical benefit.

Routine screening for bacterial vaginosis among asymptomatic pregnant women to prevent preterm birth is not recommended by public-health guidance. The CDC states that routine screening for BV in asymptomatic pregnant women (high or low risk for preterm delivery) is not recommended, a position consistent with USPSTF and endorsed by AAFP and other specialty guidance.

Major guideline bodies advise against routine BV screening in asymptomatic pregnant women and in asymptomatic women without identified risk factors for preterm birth. The USPSTF recommends against screening for BV in pregnant persons not at increased risk for preterm delivery and finds insufficient evidence to recommend screening for those at increased risk; similarly, professional guidance states that asymptomatic women and women without identified risk factors should not undergo routine screening or treatment for BV.

No explicit patient-level or test-type exclusions beyond those described elsewhere in the policy are listed in the cited sections. Procedure and laboratory codes relevant to vaginitis testing are provided for billing reference, but these code lists do not themselves constitute additional exclusions.

The policy identifies specific diagnostic modalities that are addressed in the coverage guidance. Examples called out include rapid enzyme immunoassay identification of Trichomonas (listed as not meeting coverage), and various molecular-based panel tests for vaginal flora imbalance and/or infertility that likewise do not meet coverage criteria. The document also enumerates multiple CPT/HCPCS and proprietary test codes (e.g., codes and the Xpert® Xpress MVP proprietary assay) to help identify the tests referenced.

Use of bacterial vaginosis NAATs for asymptomatic women is not supported by the CDC and therefore is not indicated for screening. The CDC recommends that BV NAATs be used among symptomatic women only, because test accuracy has not been well defined for asymptomatic populations.

Culture is not recommended for the diagnosis of bacterial vaginosis. The AAFP guidance explicitly advises: do not obtain culture for the diagnosis of BV because BV represents a polymicrobial disturbance rather than a single-culture–identifiable pathogen.

The cited chunks do not contain additional explicit ‘‘not medically necessary’’ statements beyond those already summarized in the policy sections addressing non-covered tests and exclusions. The document does, however, list procedure and proprietary test codes for reference.

Procedure and Diagnostic Codes

Covered/Referenced CPT CodesCPT

82120	Amines, vaginal fluid, qualitative.
83986	pH; body fluid, not otherwise specified.
87070	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates.
87149	Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed.
87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
87210	Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps).
87480	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique.
87481	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique.
87482	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification.
87510	Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique.

1–10 of 14

1/2

Additional/Not Otherwise Specified and Misc CodesCPT|HCPCS|Proprietary

87797	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism.
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism.
87799	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism.
87800	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique.
87801	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique.
87808	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis.
87905	Infectious agent enzymatic activity other than virus (eg, sialidase activity in vaginal fluid).
0352U	Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis; Proprietary test: Xpert® Xpress MVP (Cepheid).
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens.

Procedure CPT codes (Covered/Referenced)CPT

82120	Amines, vaginal fluid, qualitative.
83986	pH; body fluid, not otherwise specified.
87070	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates.
87149	Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed.
87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
87210	Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps).
87480	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique.
87481	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique.
87482	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification.
87510	Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique.

1–10 of 14

1/2

Reimbursement / Additional codes and proprietary test codesmixed

87797	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism.
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism.
87799	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism.
87800	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique.
87801	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique.
87808	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis.
87905	Infectious agent enzymatic activity other than virus (eg, sialidase activity in vaginal fluid).
0352U	Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis; Proprietary test: Xpert® Xpress MVP (Cepheid).
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens.

Vaginal pH thresholds

Normal premenopausal pH4.0–4.5

Elevated pH suggesting BVpH > 4.5

pH range suggesting trichomoniasispH 5–6

Normal premenarchal/postmenopausal pH≥4.7

BD MAX Vaginal Panel performance

BD MAX Vaginal Panel sensitivity90.5% (vs Amsel/Nugent)

BD MAX Vaginal Panel specificity85.8% (vs Amsel/Nugent)

Analytes detectedBV-associated bacteria, Candida species, and Trichomonas vaginalis

None listed

ListNone listed

Provider Actions, Documentation, and Billing Guidance

Documentation Required

Policy vs Government Coverage Conflict

If there is a conflict between this Policy and any relevant, applicable government policy for a particular member (e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid), the government policy will be used to make the determination. For the most up-to-date Medicare and Medicaid policies, providers should consult the CMS Medicare Coverage Database and the applicable state Medicaid website.

Refer to https://www.cms.gov/medicare-coverage-database/search.aspx for Medicare LCDs/NCDs
Consult applicable state Medicaid websites for state-specific coverage rules

Note

Prior Authorization / Plan Verification

No explicit prior authorization requirements are stated within this section. Providers should nevertheless verify member-specific benefit coverage and prior authorization rules at the time of service, as individual plan benefit designs may impose authorization requirements not described here.

Provider action: Confirm member benefits and any plan-specific prior authorization requirements before ordering tests

Billing Rule

Procedure Codes and Billing Reference

Procedure and laboratory codes related to vaginitis testing are listed below for billing and authorization reference. Use the listed CPT/HCPCS codes when requesting authorizations or submitting claims. Procedure codes in Medical Policy documents are provided as a reference and may not be all-inclusive.

Amines, vaginal fluid, qualitative: 82120
pH; body fluid: 83986
Culture, bacterial (non-urine/blood/stool): 87070
Culture identification by direct probe: 87149
Culture identification by amplified probe: 87150
Smear, wet mount: 87210
NAAT for Candida (direct probe): 87480; (amplified): 87481; (quant): 87482
NAAT for Gardnerella vaginalis (direct): 87510; (amplified): 87511; (quant): 87512
NAAT for Trichomonas vaginalis (direct): 87660; (amplified): 87661
Infectious agent detection, not otherwise specified: 87797-87799
Multiplex or multiple organism NAATs: 87800-87801
Trichomonas antigen detection by immunoassay: 87808

Note

Cost-Effectiveness and Recommended Testing Strategy

Cost-effectiveness analyses and professional guidance favor an initial targeted diagnostic strategy for symptomatic vaginitis: perform lower-cost office tests first (history, exam, pH, amine/whiff test, saline and KOH wet mount, microscopy) and reserve molecular testing or cultures for cases with negative initial testing, persistent or complicated infections, or when organism identification will alter management.

Initial lower-cost testing strategy: pH, whiff test (KOH), saline/KOH wet mount, microscopy
Targeted culture or NAAT when wet mount/pH are negative or when symptoms persist
Molecular NAATs are useful for symptomatic patients and for confirming trichomoniasis or identifying non-albicans Candida in complicated VVC

Documentation Required

Clinical Evaluation and Documentation Requirements

Providers should document a careful history, physical examination, and the results of office-based diagnostic tests (pH, amine/whiff test, saline and KOH wet mounts, microscopy) when evaluating symptomatic patients. If microscopy is unavailable or initial testing is inconclusive, document the rationale for using commercial diagnostic methods (e.g., antigen tests, NAAT/PCR) and note how results will impact treatment decisions.

Document symptoms, sexual history, vaginal hygiene practices, self-treatment, and examination findings
Record results of pH, KOH whiff test, saline and KOH wet mount, and any microscopic findings (clue cells, budding yeast, motile trichomonads)
If ordering NAATs or molecular panels, document clinical indication (symptomatic, failed empiric therapy, complicated VVC) and the expected impact on management

Definitions and Test Names

VVC — Definition

TermVulvovaginal candidiasis (VVC)

SynonymCandida vaginitis

ContextCommon cause of vaginitis; associated with normal/acidic vaginal pH

BV — Definition

TermBacterial vaginosis (BV)

Associated organismsGardnerella vaginalis, Atopobium vaginae, BV-associated bacteria

Clinical noteElevated vaginal pH often suggests BV

NAAT — Definition

AcronymNAAT

DefinitionNucleic acid amplification testing

UseMolecular detection of pathogens (e.g., Candida, Gardnerella, Trichomonas) in vaginal specimens

Aptima CV/TV and Aptima BV

Manufacturer/AssayAptima CV/TV and Aptima BV (Hologic)

Aptima CV/TV detectsCandida species group (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, and Trichomonas vaginalis

Aptima BV detectsGardnerella vaginalis, Atopobium vaginae, and certain Lactobacillus spp.; reports qualitative result for BV using algorithmic analysis

BD MAX Vaginal Panel

AssayBD MAX Vaginal Panel

MethodAutomated real-time PCR for DNA targets from BV-associated bacteria, Candida species, and Trichomonas vaginalis

Regulatory statusFDA-cleared (class III / 510(k) decision referenced)

Aptima BV — Description

AssayAptima BV

MethodTranscription-mediated amplification (TMA) targeting ribosomal RNA from BV-associated bacteria

Intended useQualitative aid in diagnosis of BV from clinician- or patient-collected vaginal swabs in symptomatic females

BD MAX Vaginal Panel — Description

AssayBD MAX Vaginal Panel

DescriptionAutomated qualitative PCR panel detecting BV-associated bacteria, Candida species, and Trichomonas vaginalis from vaginal swabs

Regulatory noteFDA-cleared with post-market labeling modifications noted by FDA

Proprietary molecular/vaginitis panels

DefinitionProprietary commercial multiplex NAAT/vaginitis panels (examples)

ExamplesXpert® Xpress MVP (Cepheid), Aptima BV, BD MAX Vaginal Panel

PurposeDetect BV-associated bacteria, Candida species, and Trichomonas vaginalis in vaginal-fluid specimens

OpenPayer

Diagnosis of Vaginitis — Coverage Criteria

Coverage Criteria for Vaginitis Testing

Procedure and Diagnostic Codes

Provider Actions, Documentation, and Billing Guidance

Background and Clinical Context

Definitions and Test Names